Dementia research news

 The Food and Drug Administration has today approved lecanemab, a new drug for Alzheimer's disease, for use across the US.

Dr Richard Oakley, Associate Director of Research at Alzheimer’s Society, has called breakthrough Alzheimer's drug donanemab, 'a turning point', as the full trial results were revealed.

Two world-class research teams will carry out countrywide trials to identify accurate and quick blood tests that can diagnose dementia, in a bid to improve the UK’s shocking diagnosis rate.

Alzheimer's Society has responded to a new study which suggests a blood test could predict dementia 15 years before diagnosis.

Alzheimer’s Society is working on the Blood Biomarker Challenge, a project that could bring dementia blood tests to the NHS within five years.